The study is testing whether an experimental medicine named prasinezumab can help protect thinking skills in these individuals. The drug is given through an IV infusion, which means it is delivered directly into the bloodstream using a small tube inserted into a vein. Participants will receive either the medicine or a placebo, a simple salt solution that looks the same as the active treatment, so that neither the participants nor the doctors know which one is given. The main goal is to see if the medicine can slow or prevent loss of mental function compared with the placebo.

People who join the trial will come to the clinic for regular visits over about two years. At each visit they will have brief safety checks such as blood tests and heart monitoring, and they will complete simple questionnaires and short memory and thinking tests that are easy to understand. The schedule includes several infusion sessions spaced out over the study period, allowing researchers to track any changes in thinking abilities and overall health throughout the trial.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

The purpose of the study is to understand how aspirin affects the chances of cancer coming back and the overall survival of patients with stage II and III colon cancer. Participants in the study will take either aspirin or a placebo every day for up to five years. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving aspirin and who is receiving the placebo, to ensure unbiased results.

Throughout the study, researchers will monitor the participants’ health to see if the cancer returns and to track their overall survival. The main goal is to see if taking aspirin can help improve survival rates over five years. The study will also look at how long patients remain free from cancer and how long they can continue the treatment without any issues. This research aims to provide valuable insights into the potential benefits of aspirin for patients who have undergone surgery for colon cancer.

The purpose of the study is to compare how well the combination of zanzalintinib and pembrolizumab works against using pembrolizumab alone in treating this type of cancer. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab by itself. Some participants may receive a placebo, which looks like the real medication but does not contain the active drug. The study will involve regular check-ups and monitoring to assess the treatment’s effects and any side effects experienced by the participants.

The study will take place over several months, with participants receiving treatment and being monitored for changes in their condition. The goal is to determine if the combination of zanzalintinib and pembrolizumab can improve outcomes for patients with this type of cancer. Participants will be closely observed by medical professionals throughout the study to ensure their safety and to gather important data on the treatment’s effectiveness.

The purpose of this study is to determine if the combination of ceralasertib and durvalumab is more effective than docetaxel in treating patients with this type of lung cancer. Participants in the study will be randomly assigned to receive either the combination therapy or docetaxel. The study will monitor the overall survival of participants, which refers to the length of time patients live after starting the treatment. Other aspects being evaluated include how long the cancer stays under control, the quality of life reported by participants, and the safety and tolerability of the treatments.

The study will take place over a period of time, with participants receiving treatment for up to 24 months. During this time, participants will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study aims to provide valuable information on the effectiveness and safety of these treatments for patients with advanced or metastatic non-small cell lung cancer.

Participants in this research will be randomly assigned to receive either REGN7508 or a placebo. This is a double-blind study, meaning that neither the participants nor the researchers know which treatment is being administered. During the course of the study, the effectiveness of the medication in preventing blood clots and its impact on the risk of bleeding will be monitored. This includes looking for any significant bleeding events to ensure the safety of the treatment.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

For those with a high amount of the protein, AZD5335 will be compared to mirvetuximab soravtansine. For those with a low amount of the protein, AZD5335 will be compared to a treatment chosen by the doctor, which may include doxorubicin hydrochloride, liposomal, topotecan, or paclitaxel. These treatments are delivered through an intravenous infusion, which means the medicine is passed directly into a vein.

During the study, participants will receive their assigned treatment and will be monitored to see how long the cancer remains stable without growing. This period is referred to as progression-free survival. The study also looks at overall survival, which is the total length of time from the start of the study until death from any cause.

The cancer being investigated is also classified as advanced or metastatic, meaning it has grown beyond the original part of the lung or has spread to other parts of the body. Participants in this trial will receive their treatment through intravenous use, which involves delivering the medication directly into a vein using a liquid solution for infusion. The study will monitor how long the cancer remains stable without growing and the overall length of time patients live during the trial.

The research compares single antiplatelet therapy (SAPT) with dual antiplatelet therapy (DAPT). Antiplatelet medications help prevent blood clots from forming. The purpose is to determine if using just one antiplatelet medication is as effective as using two in preventing complications after the procedure, while potentially reducing bleeding risks.

The study will follow patients for 12 months after their procedure to track outcomes such as death from any cause, the need for additional procedures on the treated blood vessel, and heart attacks related to the treated vessel. Quality of life and functional status will be assessed using questionnaires at different timepoints throughout the study.

The purpose of the study is to compare the effectiveness of Rilvegostomig with Pembrolizumab in treating patients with a specific type of lung cancer that has spread to other parts of the body and shows high levels of a protein called PD-L1. The study will look at how long patients live and how long they live without the cancer getting worse. Participants will receive either Rilvegostomig or Pembrolizumab as their first treatment for this type of lung cancer. The study will monitor patients over time to see how well the treatments work and to check for any side effects.

Throughout the study, researchers will collect information on how the treatments affect overall survival, which is the length of time patients live after starting the treatment, and progression-free survival, which is the time patients live without the cancer worsening. Other aspects being studied include the response rate to the treatments, the duration of the response, and any side effects experienced. The study aims to provide valuable information on the potential benefits and risks of using Rilvegostomig compared to Pembrolizumab for treating this type of lung cancer.

The purpose of the study is to evaluate the safety and initial effectiveness of the NVD-003 implant in helping bones heal. Participants in the study will receive the implant through a surgical procedure. After the surgery, they will be monitored over a period of time to check for any side effects and to see how well the bone is healing. This will involve regular check-ups and imaging tests like X-rays and CT scans to assess the progress of bone healing.

Throughout the study, the participants’ overall health and quality of life will also be evaluated. This includes monitoring pain levels and any changes in daily activities. The study aims to provide valuable information on whether this new treatment can be a safe and effective option for people with this challenging bone condition.

The purpose of this study is to evaluate how effective prasinezumab is compared to a placebo in delaying the progression of motor symptoms in people with early Parkinson’s disease. Participants in the study will receive either prasinezumab or a placebo through IV infusions. The study will monitor the time it takes for participants to experience a confirmed worsening of their motor symptoms. This will help researchers understand if prasinezumab can slow down the progression of the disease.

Throughout the study, participants will be regularly assessed to track any changes in their motor function and overall health. This includes monitoring for any side effects or adverse reactions to the treatment. The study aims to provide valuable information on the safety and effectiveness of prasinezumab for individuals with early Parkinson’s disease, potentially leading to better treatment options in the future.

The purpose of the study is to see how well DS-1062a works compared to Docetaxel in patients who have already received treatment for their lung cancer. Participants in the study will be randomly assigned to receive either DS-1062a or Docetaxel. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will last for a period of up to 72 weeks, during which time participants will receive regular infusions and have their health monitored closely by the study team.

Throughout the study, participants will undergo various assessments to track the progress of their cancer and overall health. These assessments may include imaging tests to look at the size and spread of the cancer, as well as regular check-ups to monitor any side effects from the treatments. The goal is to determine which treatment is more effective in controlling the cancer and improving the quality of life for patients with NSCLC.

The purpose of the study is to determine the best dose of IMGN151 that can be safely given to patients and to see how well it works in treating these cancers. The study will be conducted in two main phases. In the first phase, different doses of IMGN151 will be tested to find the safest and most effective dose. In the second phase, the chosen dose will be given to more patients to further assess its effectiveness. Throughout the study, participants will receive IMGN151 through an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein.

Participants in the study will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information about the potential benefits and risks of IMGN151 for women with these specific types of recurrent cancers. This research is important for developing new treatment options that could improve outcomes for patients facing these challenging conditions.

Participants in the study will receive a combination of these treatments. Initially, they will be given Paclitaxel and Carboplatin along with Durvalumab. After this initial phase, some participants will continue to receive Durvalumab alone, while others will receive Durvalumab in combination with Olaparib. The study is designed to compare these different treatment approaches to see which is most effective in preventing the cancer from progressing.

The study will be conducted over a period of time, with regular monitoring to assess the health and response of the participants to the treatments. The goal is to determine how well these treatments work in extending the time patients live without their cancer getting worse and to evaluate the overall safety of the treatment combinations. Participants will be closely observed for any side effects or changes in their condition throughout the study.

The purpose of this study is to explore the potential benefits of combining the genetic vaccine with pembrolizumab in treating patients with MSI-H or dMMR colorectal cancer. Participants in the study will receive the investigational vaccine and pembrolizumab, or a placebo, to compare the effects. The study will monitor the participants over a period of time to assess the treatment’s impact on the cancer.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to evaluate the treatment’s effectiveness. The study aims to gather information on how well the combination of the genetic vaccine and pembrolizumab works in shrinking or controlling the cancer, as well as to observe any side effects that may occur. This research could provide valuable insights into new treatment options for patients with this type of cancer.

The purpose of the study is to determine how effective and safe camizestrant is compared to fulvestrant in treating women with this type of advanced breast cancer who have gone through menopause. Participants in the study will receive either camizestrant or fulvestrant, and their progress will be monitored over time. The study will look at various outcomes, such as how long patients live without the cancer getting worse, the response of the cancer to the treatment, and any changes in the size of the tumor. Additionally, the study will assess the overall survival of participants and any changes in their quality of life.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. These tests may include imaging scans and blood tests to measure the levels of the medication in the body. The study aims to provide valuable information on the effectiveness of camizestrant compared to fulvestrant, which could help improve treatment options for women with this type of breast cancer in the future.

The purpose of this study is to find the most effective and safe dose of DF1001 for treating these tumors. Participants will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will be conducted in several parts, starting with a dose escalation phase to determine the safest dose, followed by an exploratory phase to assess the treatment’s effectiveness. The final phase will expand the study to include more patients to confirm the results.

Throughout the study, researchers will monitor participants closely to observe any side effects and measure how well the tumors respond to the treatment. The goal is to gather information that could lead to new treatment options for patients with advanced solid tumors. This study is an important step in understanding how DF1001 and its combinations can potentially improve outcomes for patients with these challenging conditions.

The purpose of the study is to compare the overall survival of patients who receive the combination of SBP-101, nab-paclitaxel, and gemcitabine with those who receive only nab-paclitaxel and gemcitabine. Participants will be randomly assigned to one of the two groups, and neither the participants nor the researchers will know who is receiving SBP-101 or the placebo. The study will involve regular visits to the clinic for treatment and monitoring, and participants will receive the medications through injections or infusions.

The study will continue for a period of time, during which the health and progress of the participants will be closely monitored. The main goal is to see if the addition of SBP-101 can improve the length of time patients live with this type of cancer. The study will also look at other factors, such as how long it takes for the cancer to progress and the overall response to the treatment. Participants will be asked to complete questionnaires about their quality of life during the study.

The purpose of the study is to determine if adding bemarituzumab to standard chemotherapy and nivolumab treatment improves survival for patients with previously untreated advanced stomach cancer. The medications are given through intravenous infusion, except for capecitabine which is taken by mouth. The study is conducted in two parts: a smaller initial phase to evaluate safety, followed by a larger phase to compare the effectiveness of the treatments.

During the study, participants will receive regular doses of the study medications and undergo various medical assessments. The treatment period may last for several months, depending on how well the participant responds to the therapy. Doctors will monitor participants’ health status, check for side effects, and evaluate how well the cancer responds to treatment throughout the study period.

Participants in the study will receive either the new treatment combination or the standard treatment. The new treatment involves the use of Dato-DXd, a medication designed to target and destroy cancer cells, and Durvalumab, which helps the immune system fight cancer. These medications will be given through an intravenous infusion, which means they are delivered directly into the bloodstream. The standard treatment includes Pembrolizumab, another medication that boosts the immune system, along with chemotherapy, which uses drugs to kill cancer cells. Some participants may also receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments.

The study will follow participants over a period of time to monitor their response to the treatments. This includes checking for the absence of cancer in the breast and lymph nodes after surgery, as well as tracking the time until any signs of cancer return or other health events occur. The goal is to see if the new treatment can improve outcomes for patients with these specific types of breast cancer. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to compare how well these treatments work in preventing the return or worsening of the cancer. Participants in the study will be divided into groups to receive either TAR-200 with Cetrelimab, TAR-200 alone, or the standard BCG treatment. The study will monitor participants over time to see how long they remain free from cancer recurrence or progression.

Throughout the study, participants will undergo various procedures, including regular check-ups and tests to assess their health and the status of their cancer. The study aims to provide valuable information on the potential benefits of these new treatment options for people with High-Risk Non-Muscle Invasive Bladder Cancer.

The purpose of this study is to find a suitable dose of zongertinib when used in combination with either trastuzumab deruxtecan or trastuzumab emtansine, and to see if these combinations can help people with these types of cancer. The study is divided into two main parts. The first part, called Phase Ib, involves gradually increasing the dose of zongertinib to determine the highest dose that can be given safely. The second part, Phase II, aims to find out how effective the treatment is at shrinking tumors or stopping them from growing. Participants will receive the study medications and be monitored for any side effects and how well the treatment is working.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their cancer. The study will help researchers understand the best way to use these medications together and whether they can provide a new treatment option for people with these advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to determine if the combination of eftilagimod alpha and paclitaxel is more effective in improving overall survival compared to paclitaxel with a placebo. Initially, the study will focus on finding the best dose of eftilagimod alpha to use with paclitaxel. After this, the main part of the study will begin, where participants will be randomly assigned to receive either the eftilagimod alpha and paclitaxel combination or paclitaxel with a placebo. The study will monitor participants over a period of time to assess the safety and effectiveness of the treatment.

Participants in the study will receive regular injections and will be closely monitored by healthcare professionals. The study aims to provide valuable information on whether eftilagimod alpha can offer a new treatment option for patients with HER2-negative/low metastatic breast cancer. The trial is expected to continue until 2027, with the goal of improving treatment outcomes for patients with this type of breast cancer.

The purpose of this study is to document the long-term safety of the NVDX3 implant. Participants in the study will have previously been involved in core clinical trials with NVDX3 and will continue to be monitored for safety over a period of 10 additional years. This involves yearly follow-up visits to ensure the implant remains safe for use over a long period. The study will collect information on any serious adverse events (SAEs) or other side effects related to the implant from the time of screening until 10 years after the initial study.

Participants in this study will have agreed to these follow-up visits and will have signed an informed consent form to confirm their understanding and willingness to participate in this long-term safety study. The study aims to provide valuable information on the safety of the NVDX3 implant for patients with the specified conditions, contributing to the understanding of its long-term effects and potential benefits.

The main purpose of this study is to determine if adding ribociclib to standard hormone therapy improves outcomes for patients with early breast cancer compared to hormone therapy alone. Ribociclib is given as a tablet that is taken by mouth, while goserelin is given as an injection under the skin. Anastrozole and letrozole are also taken as tablets.

During the study, patients will receive either the combination of ribociclib with hormone therapy or hormone therapy by itself. The treatment continues for up to 5 years, and patients will have regular check-ups to monitor their health. The study team will track how long patients remain free from cancer returning and assess the overall safety of the treatment combination.

The purpose of the study is to evaluate how effective the combination of Lorigerlimab and Docetaxel is in treating this type of prostate cancer. Participants in the study will be randomly assigned to receive either the combination of Lorigerlimab and Docetaxel or Docetaxel alone. The study will monitor the participants over a period to see how the cancer responds to the treatment. This includes checking if the cancer stops growing or shrinks, and how long it takes for the cancer to start growing again. The study will also look at the overall health and survival of the participants, as well as any side effects they may experience.

Throughout the study, participants will receive regular check-ups and tests to monitor their health and the progress of the cancer. These tests may include imaging scans and blood tests to measure the levels of prostate-specific antigen (PSA), a substance often found in higher amounts in men with prostate cancer. The study aims to provide valuable information on whether the new treatment combination can offer better outcomes for patients with Metastatic Castration-Resistant Prostate Cancer.

Participants in the study will receive various medications as part of their treatment. These include Capecitabine, Oxaliplatin, and Fluorouracil, which are commonly used in cancer treatment. Additionally, supportive medications such as Ondansetron, Dexamethasone, Folinic Acid, and Metoclopramide may be administered to help manage side effects and improve the overall treatment experience. Some patients may receive a placebo as part of the study design.

The study will follow participants over a period of time to assess outcomes such as overall survival, progression-free survival, and the occurrence of side effects. The trial aims to provide valuable information on the best treatment strategy for older patients with this type of cancer, ultimately helping to improve their quality of life and treatment outcomes.

The purpose of the study is to determine if baricitinib can help reduce the risk of death in patients with severe or critical COVID-19. Participants in the study will receive either the medication or a placebo, and their health will be monitored to see how the disease progresses. The study will look at whether the medication can prevent the disease from getting worse and if it can help patients recover more quickly.

Throughout the study, participants will be closely observed to track their recovery and any changes in their condition. The trial will also assess various health markers to understand the impact of the treatment. This research is part of a larger effort to find effective treatments for COVID-19 and improve outcomes for patients with this disease.

The purpose of the study is to evaluate how effective Bemcentinib is in improving the condition of patients with moderate COVID-19. Participants in the study will receive either Bemcentinib or a placebo, along with the usual care provided in hospitals. The study will monitor the patients’ health over a period of time to see if there are any changes in their condition, such as improvement or worsening of symptoms. The study will also look at other factors, such as how quickly patients recover and any side effects they may experience.

Throughout the study, various health indicators will be assessed, including the patients’ disease state on a scale used by the World Health Organization (WHO) and the levels of oxygen in their blood. The study will also track the occurrence of any serious health events and the time it takes for patients to be discharged from the hospital. By the end of the study, researchers hope to gather valuable information about the potential benefits and safety of using Bemcentinib to treat COVID-19.

The purpose of this study is to assess how well the combination of Magrolimab, Bevacizumab, and FOLFIRI works in patients who have already received treatment for their advanced cancer but are not eligible for certain other therapies. Participants in the study will be randomly assigned to receive either the new combination treatment or the standard treatment of Bevacizumab and FOLFIRI. The study will monitor the participants over a period of time to evaluate the progression of the disease and any side effects experienced.

Throughout the study, participants will receive the medications through intravenous infusions, which means the drugs are delivered directly into the bloodstream through a vein. The study aims to provide valuable information on whether the addition of Magrolimab to the existing treatment regimen can improve outcomes for patients with metastatic colorectal cancer. The trial will help determine the best dose and assess the safety of the new treatment combination.

The purpose of the study is to evaluate how effective Vobramitamab Duocarmazine is at two different dose levels in treating this type of prostate cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will compare the effects of the two dose levels to see which one works better in slowing down the progression of the cancer. Some participants may also receive a placebo, which is a substance with no active medication, to help researchers understand the true effects of the treatment.

Throughout the study, participants will be monitored regularly to assess how the cancer is responding to the treatment. This will involve various tests and scans, such as MRI or computed tomography (CT), to check for changes in the cancer. The study aims to provide valuable information on the potential benefits and safety of Vobramitamab Duocarmazine for patients with this challenging form of prostate cancer. The trial is expected to continue for a period of time to gather enough data to make informed conclusions about the treatment’s effectiveness.

The purpose of the study is to evaluate how well the combination of Carboplatin and Mirvetuximab Soravtansine works in treating these cancers. Initially, patients will receive both Carboplatin and Mirvetuximab Soravtansine together. After this phase, patients will continue treatment with Mirvetuximab Soravtansine alone. The study aims to see if this treatment approach can help control the cancer in patients who have shown sensitivity to platinum-based chemotherapy in the past.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the response of the cancer to the treatment over time. This trial is open-label, meaning both the researchers and participants know which treatments are being administered. The study will help determine the effectiveness of this treatment combination in managing these specific types of cancer.

Participants in the study will receive either Trilaciclib or a placebo before their Topotecan chemotherapy sessions. The study will monitor the overall survival of patients, which means the length of time patients live after starting the treatment. The trial will also look at other factors, such as how the cancer responds to the treatment and any side effects that may occur. The study is designed to last for a period of up to 120 days, during which patients will receive regular intravenous infusions of the study medications.

In addition to Trilaciclib and Topotecan, the study involves the use of other substances like Sodium Chloride and Glucose Monohydrate, which are commonly used in medical settings to support the administration of intravenous treatments. The trial aims to provide valuable information on the effectiveness and safety of using Trilaciclib in combination with Topotecan for treating patients with ES-SCLC.

Participants in the study will receive chemotherapy with or without pembrolizumab, followed by maintenance treatment with olaparib or a placebo. The study will be conducted over a period of time, with regular monitoring to assess the progression of the disease. The treatments will be administered through intravenous infusions or oral tablets, depending on the specific medication.

The study aims to provide valuable information on how these treatments can help manage advanced epithelial ovarian cancer, particularly in patients without BRCA mutations. The results will help determine the best treatment options for improving the quality of life and survival rates for individuals with this type of cancer.